Antibody-drug conjugates (ADC) market Key Players, Revenue Size & Share, Industry Analysis

Antibody Drug Conjugate market to Experience Scaling from 2017 to 2023

is about to experience an astounding CAGR of 19% during the forecast period (2017-2023), opines Market Research Future (MRFR). These biopharmaceutical medications have proven effective against cancer when introduced as targeted therapy. Its ability to eliminate cancer cells without harming the healthy ones and giving patients a better chance to recover is one of the prime advantages for its global demand.

Drivers and Restraints:

The market is about to witness a rise in demand for ADCs owing to the prevalence of chronic diseases such as cancer. With the rising population, the number of people affected by the disease is also on the rise. ADCs offer a better fighting chance against the disease, and by giving a faster recovery time, it reinstalls hope in patients. This has also given rise to the demand for ADCs. Also, the advances in linker technology have widened the scope of ADC improvisation. Efforts towards patent protection can provide the ADC market a boost and a robust shape.

However, ADCs incur heavy cost as the production has both upstream and downstream hurdles that affect the feasibility. Moreover, the lack of experienced hands and regulatory challenges can prove as impediments for the market during the forecast period.

Industry Trends:

The market is still developing and each day brings in new information regarding advancements. Efforts of Creative Biolabs in introducing a maytansinoid-payload for ADCs better performance can be considered exemplary. In ADCs, the link between the antibody and the cytotoxic agent is crucial. Broadpharm has introduced a polyethylene glycol (PEG) product, a linker that has features such as high water solubility, reduced aggregation, and low immunogenicity. In addition, Glykos Finland and OcellO of The Netherlands have developed a hydrophilic auristatin payload that betters ADCs efficacy and biocompatibility.

Regional Segmentation: Antibody Drug Conjugate market

Region-wise, the antibody drug conjugates market covers namely North America, Europe, Asia Pacific (APAC) and the Middle East and Africa (MEA).

North America has the largest market owing to the rising number of cancer patients in the region and increasing health awareness. The well-structured healthcare industry is also a significant factor that is promoting the medicine.

Europe is second in terms of volume of the market. The regional market experiences the same features as that of North America. In addition, the governments are also funding cancer-related industries heavily and have developed a robust infrastructure which helps in generating market share.

APAC has a huge market owing to the presence of developing countries such as India and China with a large population base that also has a significant number of patients with cancer. Furthermore, the region is open to adopting the latest technologies and integrates western treatment options in its regulatory framework to improve the quality of public life.

Market Competition:

The market is quite open and encourages innovation to simplify complex production methods. For instance, WuXi Biologics started construction of a research & development and manufacturing center that would showcase state-of-the-art technologies and eyes a global expansion. Also, ADC Biotechnology has successfully secured substantial funding from Downing LLP, a London-based investment management firm. Sanofi, in collaboration with Meditope Biosciences, has developed a bioconjugation platform to develop better medicines. 

Some major players in the global antibody-drug conjugate market include SeattleGenetics (US), ImmunoGen, Inc. (US), Immunomedics (US), Roche Holding AG (Switzerland), Antikor (UK),  Genentech (US), Concortis Biotherapeutics (US), Agensys, Inc. (US), Celldex Therapeutics (US), Millennium Pharmaceuticals (US), Pfizer Inc. (US), and others.

Antibody Drug Conjugate Market: By Types (Monoclonal Antibodies, Linker), Product (Adcertis, Kadcyla) Technology (Immunogen Technology, Immunomedics Technology), Applications (Leukemia, Lymphoma) End-Users (Biotechnology Companies) - Forecast 2023 :